Zentalis Pharmaceuticals (ZNTL) Receivables - Accured (2020 - 2026)

Zentalis Pharmaceuticals has reported Receivables - Accured for 7 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Accured fell 23.27% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (down 23.27% YoY), and the FY2025 full-year result was $1.9 million, down 34.49% from the prior year.
• Receivables - Accured for Q1 2026 stood at $2.1 million, up from $1.9 million in the prior quarter.
• The five-year high for Receivables - Accured was $3.3 million in Q4 2023, with the low at $266000.0 in Q1 2022.
• Average Receivables - Accured over 5 years is $1.9 million, with a median of $2.1 million recorded in 2026.
• Year-over-year, Receivables - Accured jumped 719.48% in 2024 and tumbled 34.83% in 2025.
• Tracing ZNTL's Receivables - Accured over 5 years: stood at $508000.0 in 2022, then soared by 556.89% to $3.3 million in 2023, then declined by 11.81% to $2.9 million in 2024, then plunged by 34.49% to $1.9 million in 2025, then gained by 8.97% to $2.1 million in 2026.
• The last three Receivables - Accured figures came in at $2.1 million (Q1 2026), $1.9 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.

Peer Comparison